Avenue Therapeutics, Inc. (ATXI): Cash & Equivalents
$2.85M
As of 2025-12-31
$1.94M
As of 2026-06-30
-24.8%
3-year compound annual growth
-1.8%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.85M | +10.1% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $2.59M | +45.5% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $1.78M | -73.4% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $6.71M | +78.3% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $3.76M | +20.1% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $3.13M | -64.2% | 2022-03-25, Balance as of period end |
| 2019-12-31 | $8.74M | +227.4% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $2.67M | -77.3% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $11.78M | n/m | 2019-03-12, Balance as of period end |
| 2016-12-31 | $197.0K | n/m | 2018-03-01, Balance as of period end |
| 2015-12-31 | $14.0K | n/a | 2018-03-01, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.85M | +10.1% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $3.04M | +39.8% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $7.80M | +440.3% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.8K | -16.3% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $405.0K | -66.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $18.62M | +394.9% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.66M | -75.8% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
Compare ATXI, NWBO, NRXP, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗